[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Atea Pharmaceuticals Q1 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved...

AVIR : 4.87 (-2.21%)
Atea Pharmaceuticals Engages Evercore to Explore Strategic Partnerships for HCV Program

Atea Pharmaceuticals is exploring strategic partnerships to enhance shareholder value related to its hepatitis C treatment program.Quiver AI SummaryAtea Pharmaceuticals, Inc. has announced the engagement...

AVIR : 4.87 (-2.21%)
Atea Pharmaceuticals Reports 98% Sustained Virologic Response in Phase 2 Study of Hepatitis C Treatment, Plans Phase 3 Program for 2025

Atea Pharmaceuticals reports 98% sustained virologic response in Phase 2 HCV study; Phase 3 trials expected to begin in 2025.Quiver AI SummaryAtea Pharmaceuticals announced the successful results of its...

AVIR : 4.87 (-2.21%)
Atea Pharmaceuticals CEO to Present Business Update at Evercore HealthCONx Conference on December 4, 2024

Atea Pharmaceuticals will present a business update at the Evercore HealthCONx Conference on December 4, 2024.Quiver AI SummaryAtea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi,...

AVIR : 4.87 (-2.21%)
Atea Pharmaceuticals Presents Promising Phase 2 Data on Bemnifosbuvir and Ruzasvir Combination for Hepatitis C at The Liver Meeting 2024

Atea Pharmaceuticals presents Phase 2 data on bemnifosbuvir and ruzasvir as potential hepatitis C treatments at AASLD 2024.Quiver AI SummaryAtea Pharmaceuticals, Inc. has presented three poster presentations...

AVIR : 4.87 (-2.21%)
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...

FOLD : 14.49 (+0.21%)
AVIR : 4.87 (-2.21%)
CRSP : 61.89 (+3.01%)
APLS : 41.03 (-0.07%)
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates

Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...

BEAM : 35.32 (+1.52%)
FOLD : 14.49 (+0.21%)
AVIR : 4.87 (-2.21%)
CRSP : 61.89 (+3.01%)
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings

TransMedics Group TMDX is scheduled to report third-quarter 2024 results on Oct. 28, after market close.In the last reported quarter, the company’s adjusted earnings per share of 35 cents surpassed the...

AVIR : 4.87 (-2.21%)
MASI : 179.95 (+0.01%)
TMDX : 71.23 (+3.44%)
RDNT : 68.92 (+0.25%)
HSIC Gears Up for Q3 Earnings: Here's What You Need to Know

Henry Schein, Inc. HSIC is scheduled to release third-quarter 2024 results on Nov. 5, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.23,...

AVIR : 4.87 (-2.21%)
HSIC : 86.62 (+0.22%)
TMDX : 71.23 (+3.44%)
RDNT : 68.92 (+0.25%)
BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell.The company posted adjusted earnings per share (EPS) of $3.11 in the last reported...

AVIR : 4.87 (-2.21%)
BIO : 295.15 (-0.58%)
TMDX : 71.23 (+3.44%)
RDNT : 68.92 (+0.25%)

Barchart Exclusives

The 3 Best Buy-and-Hold Dividend Stocks to Load Up on for Lifetime Income
These three dividend stalwarts have rewarded shareholders with decades of steadily rising income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.